Breaking News Instant updates and real-time market news.

AA

Alcoa

$20.84

0.56 (2.76%)

, ALB

Albemarle

$68.40

3.05 (4.67%)

04:55
09/11/19
09/11
04:55
09/11/19
04:55

Credit Suisse to hold a conference

32nd Annual Basic Materials Conference will be held in New York on September 9-11.

AA

Alcoa

$20.84

0.56 (2.76%)

ALB

Albemarle

$68.40

3.05 (4.67%)

APD

Air Products

$213.79

-4.67 (-2.14%)

AVY

Avery Dennison

$113.65

0.25 (0.22%)

AXTA

Axalta Coating

$30.56

-0.09 (-0.29%)

BASFY

BASF

$0.00

(0.00%)

BAYRY

Bayer

$0.00

(0.00%)

CF

CF Industries

$50.79

1.96 (4.01%)

CLF

Cleveland-Cliffs

$7.76

0.19 (2.51%)

CMC

Commercial Metals

$17.20

0.685 (4.15%)

CMP

Compass Minerals

$53.78

1.11 (2.11%)

CTVA

Corteva

$28.30

-0.2 (-0.70%)

ECL

Ecolab

$197.09

-2.51 (-1.26%)

WLK

Westlake Chemical

$65.34

1.69 (2.66%)

TROX

Tronox

$8.93

0.27 (3.12%)

STZHF

Stelco Holdings

$0.00

(0.00%)

SHW

Sherwin-Williams

$521.07

6.37 (1.24%)

POG

Patina Oil & Gas

$0.00

(0.00%)

MOS

Mosaic

$21.38

1.21 (6.00%)

LXU

LSB Industries

$5.73

0.485 (9.26%)

LTHM

Livent

$6.86

0.1 (1.48%)

IOSP

Innospec

$90.85

1.72 (1.93%)

GRA

W.R. Grace

$69.78

-0.12 (-0.17%)

FMC

FMC Corporation

$86.58

-0.46 (-0.53%)

  • 11

    Sep

  • 11

    Sep

  • 12

    Sep

  • 12

    Sep

  • 13

    Sep

  • 13

    Sep

  • 15

    Sep

  • 17

    Sep

  • 23

    Sep

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 01

    Oct

  • 16

    Oct

  • 31

    Oct

  • 06

    Nov

  • 13

    Nov

AA Alcoa
$20.84

0.56 (2.76%)

07/18/19
JEFF
07/18/19
DOWNGRADE
Target $23
JEFF
Hold
Jefferies downgrades Alcoa to Hold, cuts price target to $23 from $29
Jefferies analyst Christopher LaFemina downgraded Alcoa to Hold from Buy and lowered his price target for the shares to $23 from $29. The stock in after-hours trading is down 21c to $23.20. The shares are inexpensive on some metrics following yesterday's Q2 results, but that alone is not reason enough to buy them, LaFemina tells investors in a research note after Thursday's closing bell. The company is not generating free cash flow, not returning large-scale capital to shareholders, and is leveraged to commodities with relatively poor fundamentals, contends the analyst. As such, he sees a lack of positive catalysts for the shares.
07/19/19
ARGS
07/19/19
DOWNGRADE
ARGS
Hold
Alcoa downgraded to Hold from Buy at Argus
07/19/19
07/19/19
DOWNGRADE

Hold
Alcoa downgraded to Hold at Argus on weaker outlook
As previously reported, Argus analyst David Coleman downgraded Alcoa to Hold after its reported Q2 net loss and reduced 2019 guidance along with the management's expectations of lower aluminum demand growth this year from trade tensions and macro headwinds. The analyst is also cutting his FY19 EPS view to (12c) from 90c and his FY20 forecast to $1.12 from $3.40. Coleman contends that the underperformance in Alcoa shares last quarter could provide long-term investors with a favorable entry point, but he sees upside for the shares in the near term as limited.
07/19/19
07/19/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. SAP (SAP) downgraded to Hold from Buy at Deutsche Bank with analyst Alex Tout saying he believes the company's momentum in Q2 fell short of what was needed for the shares to re-rate higher. 2. Alcoa (AA) downgraded to Hold from Buy at Argus and Jefferies. 3. Paycom (PAYC) downgraded to Hold from Buy at Jefferies with analyst Samad Samana citing valuation. 4. Michaels (MIK) downgraded to Underperform from Neutral at BofA/Merrill with analyst Elizabeth Suzuki citing a U.S. arts and crafts consumer survey that she said gave some color on why the company's same-store sales growth has been "lackluster. 5. News Corp. (NWSA) downgraded to Underweight from Neutral at JPMorgan with analyst Alexia Quadrani saying while the stock may appear attractively valued, she has little conviction in forward estimates. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ALB Albemarle
$68.40

3.05 (4.67%)

08/14/19
VERF
08/14/19
NO CHANGE
VERF
Albemarle price target lowered to $39.80 from $58.50 at Vertical Group
Vertical Group analyst James Bardowski lowered his price target for Albemarle to $39.80 from $58.50 citing growth concerns following the company's decision to shelve ~47% of its previously planned lithium conversion capacity. The "abrupt change" in capacity plans away from "higher-value" lithium hydroxide will leave Albemarle "significantly more" levered to its spodumene mines in Australia, Bardowski told investors earlier in a research note. Further, the analyst points out that his work suggests spodumene is currently the most oversupplied segment of the lithium market. As such, he believes the company's decision implies lower future earnings potential. The analyst keeps a Sell rating on shares of Albemarle, whose stock is down 4% to $65.99 in early trading.
08/14/19
RBCM
08/14/19
NO CHANGE
Target $83
RBCM
Outperform
Albemarle price target lowered to $83 from $89 at RBC Capital
RBC Capital analyst Arun Viswanathan lowered his price target on Albemarle to $83 to reflect the "ample near-term lithium supply", citing the company's recent decision to suspend part of its lithium conversion expansion plans due to to higher than expected industry inventory levels. The analyst is keeping his Outperform rating on the stock however with a positive view on its "responsible" capital expenditure decisions and its "leadership role" to limit the lithium supply overbuild. Viswanathan also sees Albemarle as "well-diversified" with its technology, which could "provide an advantage" relative to lithium producers that took larger battery chemistry bets.
08/09/19
OPCO
08/09/19
NO CHANGE
Target $128
OPCO
Outperform
Albemarle price target lowered to $128 from $157 at Oppenheimer
Oppenheimer analyst Colin Rusch lowered his price target for Albermarle to $128 from $157 and maintained an Outperform rating following the company's earnings report. While Albermarle is maintaining its lithium demand expectations through 2025, Rusch tells investors in a research note that he is encouraged to see the company align its growth with the pace of EV ramps and adjust product mix plans toward lithium hydroxide given OEM migration to hydroxide for EV batteries.
08/09/19
RHCO
08/09/19
NO CHANGE
Target $100
RHCO
Buy
Albemarle price target lowered to $100 from $120 at SunTrust
SunTrust analyst James Sheehan lowered his price target on Albemarle to $100 after its below-consensus Q2 revenue and its decision to delay the $1.5B in capex driven by "fears of a long term oversupply". The analyst is keeping his Buy rating on the stock longer term and contends that the demand for battery grade lithium from electric vehicles remains on track. Sheehan adds that the current 7.6-times expected forward EBITDA multiple "significantly undervalues the high-margin growth potential" of Albemarle.
APD Air Products
$213.79

-4.67 (-2.14%)

08/01/19
08/01/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Prudential (PRU) downgraded to Neutral from Buy at B. Riley FBR with analyst Randy Binner citing the company's Q2 results. 2. SBA Communications (SBAC) downgraded to Neutral from Overweight at JPMorgan. 3. Air Products (APD) downgraded to Hold from Buy at HSBC with analyst Sriharsha Pappu citing valuation for the downgrade. 4. T2 Biosystems (TTOO) downgraded to Neutral from Buy at Alliance Global Partners. 5. Corning (GLW) downgraded to Neutral from Positive at Susquehanna with analyst Mehdi Hosseini downgraded Corning (GLW) to Neutral from Positive with analyst Mehdi Hosseini saying he moved to the sidelines until he is convinced earnings and CAGR can exceed the earnings from the S&P500. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/19/19
08/19/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Air Products (APD) downgraded to Neutral from Positive at Susquehanna. 2. Whiting Petroleum (WLL) downgraded to Sector Perform from Outperform at Scotiabank and to Equal Weight from Overweight at Stephens. 3. Celgene (CELG) and Amgen (AMGN) downgraded to Neutral from Buy at Mizuho. 4. Alliance Resource Partners (ARLP) and Peabody Energy (BTU) downgraded to Neutral from Overweight at JPMorgan. 5. Trillium Therapeutics (TRIL) downgraded to Neutral from Buy at H.C. Wainwright with analyst Swayampakula Ramakanth saying the stock's 80% drop in price to 26c per share from $1.32 in the last six months could "lead to a cash crunch," leaving significant risk for its ability to raise sufficient capital to fund ongoing clinical studies. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/12/19
BMOC
08/12/19
NO CHANGE
Target $252
BMOC
Outperform
Air Products price target raised to $252 from $235 at BMO Capital
BMO Capital analyst John McNulty raised his price target on Air Products to $252 and kept his Outperform rating after meeting with its management, saying the discussions supported his conviction in the company's "significant" tailwinds. The analyst believes Air Products will continue to outperform the broader chemical and industrial space with strong pricing and capital deployment that will drive future growth.
08/19/19
SUSQ
08/19/19
DOWNGRADE
SUSQ
Neutral
Air Products downgraded to Neutral from Positive at Susquehanna
AVY Avery Dennison
$113.65

0.25 (0.22%)

07/12/19
BOFA
07/12/19
DOWNGRADE
BOFA
Neutral
Avery Dennison downgraded to Neutral from Buy at BofA/Merrill
BofA Merrill Lynch analyst George Staphos downgraded Avery Dennison to Neutral from Buy, stating that he expects sluggish Q2 revenue trends in the packaging and paper space and he favors a strategy of being overweight the combination of rigid packaging and some "lower quality stocks" that could benefit from an uptick in emerging markets and trade deal sentiment. Avery should benefit from restructuring and operating leverage in Retail Branding & Information Solutions, but he cites the stock's recent outperformance and potential volume challenges in Label & Graphic Materials for his lower rating.
04/18/19
JPMS
04/18/19
DOWNGRADE
Target $105
JPMS
Underweight
JPMorgan downgrades Avery Dennison to Underweight after 26% rally
JPMorgan analyst Jeffrey Zekauskas downgraded Avery Dennison to Underweight from Neutral with an unchanged price target of $105. Avery shares increased 26% year-to-date without improvement in business fundamentals, and "arguably some deterioration," Zekauskas tells investors in a research note. The company's trading multiple is high and business fundamentals seem to be decelerating, says the analyst. He believes "earnings bumps along the way" could negatively impact Avery Dennison's valuation.
04/18/19
JPMS
04/18/19
DOWNGRADE
Target $105
JPMS
Underweight
Avery Dennison downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Jeffrey Zekauskas downgraded Avery Dennison to Underweight from Neutral with an unchanged price target of $105.
08/16/19
BREN
08/16/19
INITIATION
Target $130
BREN
Buy
Avery Dennison initiated with a Buy at Berenberg (yesterday)
Berenberg analyst Paretosh Misra yesterday imitated coverage of Avery Dennison with a Buy rating and $130 price target. The analyst believes the company can deliver above-GDP growth and expand margins through 2021, leading to a "re-rating" of the shares.
AXTA Axalta Coating
$30.56

-0.09 (-0.29%)

07/25/19
BARD
07/25/19
NO CHANGE
Target $35
BARD
Outperform
Axalta Coating price target raised to $35 from $30 at Baird
Baird analyst Ghansham Panjabi raised his price target for Axalta Coating Systems to $35 from $30 and reiterates an Outperform rating on the shares following the company's Q2 results. While volume challenges across Axalta's portfolio will likely persist through the second half of 2019, execution on pricing should continue to drive margin expansion over the next few quarters, Panjabi tells investors in a research note. The analyst finds the stock attractive at current levels, "irrespective of any event driven outcome."
07/12/19
07/12/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Slack Technologies (WORK) and Zoom Video (ZM) were initiated with an Overweight at Stephens. 2. Fate Therapeutics (FATE) initiated with an Outperform at Oppenheimer. 3. Ameris Bancorp (ABCB) initiated with an Outperform at Raymond James. 4. TriCo Bancshares (TCBK) initiated with a Neutral at Piper Jaffray. 5. Axalta Coating (AXTA) initiated with a Buy at Berenberg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/16/19
BOFA
08/16/19
NO CHANGE
BOFA
BofA/Merrill shakes up ratings in chemicals space with 2 upgrades, 4 downgrades
BofA Merrill Lynch analyst Steve Byrne said it appears that risks of U.S. economic contagion from the broader global macro slowdown are "steadily building." Given this view, he has generally moved to be more cautious on the earnings outlook and ratings for stocks with global industrial exposure, resulting in his upgrade of two chemicals stocks and his downgrades of four others. Byrne downgraded Dow Inc. (DOW) to Underperform from Neutral and Westlake Chemical (WLK) to Underperform from Buy, noting their commodity exposure. He downgraded Axalta Coating (AXTA) to Neutral from Buy and cut PPG (PPG) to Underperform from Neutral as he is getting more cautious about their revenue prospects. He upgraded Venator Materials (VNTR) to Buy from Underperform, citing what he views as an attractive risk-reward as he expects earnings will grow in 2020, driven by product upgrades and productivity initiatives. Byrne also upgraded Nutrien (NTR) to Neutral from Underperform as he believes Ag stocks could prove to be defensive plays.
08/16/19
BOFA
08/16/19
DOWNGRADE
BOFA
Neutral
Axalta Coating downgraded to Neutral from Buy at BofA/Merrill
BASFY BASF
$0.00

(0.00%)

07/17/19
GSCO
07/17/19
DOWNGRADE
Target $31
GSCO
Sell
Trinseo downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Robert Koort said he believes investor expectations are muted ahead of Q2 earnings from the chemicals names. As proof, he noted that five negative pre-announcements - from LyondellBasell (LYB), Westlake Chemical (WLK), H.B. Fuller (FUL), Olin (OLN) and BASF (BASFY) - have been followed by a "modest" 1% average decline on the first full trading day following each announcement. In the preview note, he downgraded Trinseo (TSE) to Sell from Neutral, stating that he views styrene as the least favored commodity for cyclicals within his coverage. Koort expects styrene operating rates to decline 6 percentage points through 2022 as Chinese capacity additions outpace his "ambitious" demand growth estimate of 2.3%, he noted. Koort lowered his price target for Trinseo shares to $31.
07/09/19
JPMS
07/09/19
DOWNGRADE
JPMS
Neutral
BASF downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Chetan Udeshi downgraded BASF to Neutral from Overweight and lowered his price target for the shares to 59 euros from 72 euros following yesterday's profit earnings.
07/09/19
HSBC
07/09/19
DOWNGRADE
HSBC
Hold
BASF downgraded to Hold from Buy at HSBC
HSBC analyst Sriharsha Pappu downgraded BASF to Hold from Buy with a reduced price target of 61 euros.
09/10/19
SBSH
09/10/19
DOWNGRADE
SBSH
Neutral
BASF downgraded to Neutral from Buy at Citi
Citi downgraded BASF to Neutral from Buy.
BAYRY Bayer
$0.00

(0.00%)

07/10/19
WBLR
07/10/19
NO CHANGE
WBLR
Market Perform
Elanco combination with Bayer unlikely for many reasons, says William Blair
Shares of Elanco Animal Health (ELAN) have been unusually volatility over the past two days, William Blair analyst John Kreger tells investors in a research note. On Monday, the FDA approved a generic version of the company's largest product, Rumensin, and yesterday, the media reported speculation that Bayer (BAYRY) has approached Elanco about combining their animal health businesses, the analyst explains. He believes that while a negative development, the Rumensin generic had been expected and thus does not change his modeling assumptions. The Bayer speculation is more surprising but does not seem likely to happen "for a number of reasons," says Kreger. Elanco's largest challenge is bolstering its organic revenue growth, and buying a large company that is growing at a slower pace would only add to this challenge, according the analyst. Further, Elanco has committed to deleverage its balance sheet in the coming year, he adds. And lastly, Kreger believes there could be antitrust challenges from such a large combination. He keeps a Market Perform rating on Elanco shares.
08/15/19
UBSW
08/15/19
UPGRADE
Target $30
UBSW
Neutral
Elanco upgraded to Neutral from Sell at UBS
UBS analyst Navin Jacob upgraded Elanco Animal Health (ELAN) to Neutral from Sell with a price target of $30, down from $31. While the analyst still see risks to the company's fundamentals from African swine fever and generic Rumensin, he believes the shares are more fairly valued at current levels. Further, some of these headwinds may be offset by companion animal strength, Jacob tells investors in a research note. While concerns of a potential deal with Bayer (BAYRY) have pushed Elanco shares lower, "forecastable" concerns are built in at current levels, says the analyst.
08/26/19
BOFA
08/26/19
DOWNGRADE
Target $30
BOFA
Neutral
BofA/Merrill downgrades Elanco to Neutral on Bayer deal uncertainty
BofA/Merrill analyst Michael Ryskin downgraded Elanco Animal Health (ELAN) to Neutral from Buy with a $30 price target. While the acquisition of Bayer's (BAYRY) Animal Health business could turn out positive in the longer term, there is too much uncertainty in the near-term, including which parts of the portfolio will be divested due to antitrust issues, Ryskin tells investors in a research note. The analyst does not expect answers until nearer to deal close, which is expected in mid-2020.
06/04/19
PIPR
06/04/19
NO CHANGE
Target $32
PIPR
Overweight
Piper remains buyer of Arvinas after 'transformative' Bayer alliance
Piper Jaffray analyst Edward Tenthoff views Arvinas' (ARVN) alliance with Bayer (BAYRY) as "transformative." He's a buyer of the stock ahead of the Phase I ARV-110 data in metastatic castrate resistance prostate cancer in the second half of 2019. The analyst estimates Arvinas now holds pro forma cash of $225M to fund operations into the second half of 2021. Tenthoff reiterates an Overweight rating on Bayer with a $32 price target.
CF CF Industries
$50.79

1.96 (4.01%)

08/05/19
08/05/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Target (TGT) upgraded to Buy from Hold at Deutsche Bank with analyst Paul Trussell saying Target is "growing profitably" with EBITDA dollars up mid-single-digits in Q1, a pace that can be sustained through supply chain enhancements, market share gains in key categories often with higher margin private brands, and strong returns on remodels and new small format stores. 2. Owens-Illinois (OI) upgraded to Neutral from Sell at Goldman Sachs with analyst Brian Maguire saying the negative catalysts around lower volume and higher taxes have materialized with the stock underperforming since reporting a miss in Q2 earnings last week. 3. AB InBev (BUD) upgraded to Hold from Underperform at Jefferies with analyst saying the company is pivoting to growth while concerns on its leverage are easing. 4. CF Industries (CF) upgraded to Neutral from Underperform at BofA/Merrill with analyst Steve Byrne saying the company's "strong" Q2 results show operational strength and an improving outlook. 5. Builders FirstSource (BLDR) upgraded to In Line from Underperform at Evercore ISI. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/06/19
SUSQ
08/06/19
NO CHANGE
Target $56
SUSQ
Positive
CF Industries price target raised to $66 from $56 at Susquehanna
Susquehanna analyst Don Carson raised his price target on CF Industries to $66 from $56 as US growers are expected to plant more corn the next two planting seasons in order to rebuild corn stocks from an expected seven-year low at the end of the marketing year. The analyst said this creates a positive near-term demand environment for nitrogen fertilizer. Carson reiterated his Positive rating on CF Industries shares.
08/05/19
BOFA
08/05/19
UPGRADE
BOFA
Neutral
CF Industries upgraded to Neutral from Underperform at BofA/Merrill
08/05/19
BOFA
08/05/19
UPGRADE
Target $56
BOFA
Neutral
CF Industries upgraded to Neutral from Underperform at BofA/Merrill
BofA/Merrill analyst Steve Byrne upgraded CF Industries to Neutral from Underperform and raised his price target for the shares to $56 from $38. The company's "strong" Q2 results show operational strength and an improving outlook, Byrne tells investors in a research note.
CLF Cleveland-Cliffs
$7.76

0.19 (2.51%)

06/26/19
JEFF
06/26/19
NO CHANGE
JEFF
Nucor flat rolled price increase likely to help sentiment, says Jefferies
After Nucor (NUE) announced a $40/t flat rolled price increase yesterday, which was the first increase since February, Jefferies analyst Martin Englert said he thinks peers are likely to follow. While the increase may not immediately raise prices, it is a move in the right direction that aids more positive sector sentiment, Englert tell investors. The analyst, who advises investors to increase exposure to steel stocks, names Nucor, Steel Dynamics (STLD), Cleveland-Cliffs (CLF) and Commercial Metals (CMC) as his top U.S. picks Other publicly traded companies in the steel space include AK Steel (AKS), ArcelorMittal (MT), TimkenSteel (TMST) and U.S. Steel (X).
04/26/19
FBCO
04/26/19
UPGRADE
Target $14
FBCO
Outperform
Cleveland-Cliffs upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Curt Woodworth upgraded Cleveland-Cliffs to Outperform from Neutral and raised his price target to $14 from $13 following the company's Q1 results. In a research note to investors, Woodworth says he sees potential value near $16-$18 once the HBI plant is fully ramped, even with low hot-rolled coil prices at that point in time. He also forecasts substantially higher NAV uplift from HBI and now models EBITDA accretion of roughly $200M.
05/13/19
KEYB
05/13/19
NO CHANGE
KEYB
Chinese tariffs negative for Schnitzer Steel, positive for Luxfer, says KeyBanc
KeyBanc analyst Philip Gibbs notes that the Trump administration announced the U.S. will be ratcheting up import tariffs to 25% from 10% on about $200B worth of Chinese goods. All else equal, Gibbs sees this as a modest negative for steel producers as key consumables remain sticky, and a relative neutral for ArcelorMittal (MT) given its global exposure. On steelmaking raw materials, the analyst sees this as a neutral for Cleveland-Cliffs (CLF) and a negative for Schnitzer Steel (SCHN), with the latter in the heart of challenged non-ferrous export markets. He also views this largely as a neutral for distributors, with perhaps a modest positive of Worthington's (WOR) Cylinders segment. Clearer winners appear to be Global Brass and Copper (BRSS), Luxfer (LXFR), and Materion (MTRN), whereby it will be tougher for the Chinese to compete within the U.S. in its core businesses.
04/26/19
04/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Cleveland-Cliffs (CLF) upgraded to Outperform from Neutral at Credit Suisse with analyst Curt Woodworth saying he sees potential value near $16-$18 once the HBI plant is fully ramped, even with low hot-rolled coil prices at that point in time. 2. Argo Group (ARGO) upgraded to Outperform from Market Perform at William Blair with analyst Adam Klauber saying Argo is beginning to emerge as a long-term midcap growth insurer, Klauber tells investors in a research note. 3. Illinois Tool Works (ITW) upgraded to Neutral from Underweight at JPMorgan with analyst Ann Duignan saying following the company's "solid" Q1 results, downside risk to 2019 earnings estimates "appears limited," with the worst of auto builds and European weakness "likely behind us." 4. The Medicines Co. (MDCO) upgraded to Buy from Neutral at Goldman Sachs while Esperion (ESPR) upgraded to Neutral from Sell. 5. Shutterfly (SFLY) upgraded to Outperform from Market Perform at Raymond James with analyst Aaron Kessler citing stable Consumer segment growth trends and his expectation for improved consumer growth throughout 2019, as well as "very achievable" 2021 EBITDA guidance of $400M-$450M with modest organic growth assumptions and modest Lifetouch synergies baked in. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CMC Commercial Metals
$17.20

0.685 (4.15%)

07/10/19
DBAB
07/10/19
DOWNGRADE
DBAB
Hold
Commercial Metals downgraded to Hold from Buy at Deutsche Bank
07/11/19
DBAB
07/11/19
DOWNGRADE
Target $18
DBAB
Hold
Commercial Metals downgraded to Hold on valuation at Deutsche Bank
Deutsche Bank analyst Chris Terry last night downgraded Commercial Metals to Hold from Buy and lowered his price target for the shares to $18 from $22. The analyst cites valuation for the downgrade following the stock's outperformance relative to peers year-to-date. He believes shares are fairly valued at current levels.
03/22/19
MACQ
03/22/19
UPGRADE
MACQ
Outperform
Commercial Metals upgraded to Outperform at Macquarie
As previously reported, Macquarie upgraded Commercial Metals to Outperform from Neutral and raised its price target to $21 from $17 following the Q2 beat. Analyst David Lipschiz said metal margins are expected to expand from current levels on remaining rebar prices and believes the fabrication segment will return to profit in 2020.
CMP Compass Minerals
$53.78

1.11 (2.11%)

11/27/18
11/27/18
UPGRADE
Target $49

Neutral
Compass Minerals upgraded to Neutral on symmetric risk/reward at Credit Suisse
As previously reported, Credit Suisse analyst Christopher Parkinson upgraded Compass Minerals to Neutral from Underperform, with $49 price target. While the analyst is not more positive on its story, the -29% move since February reflects investors' frustration with its inability to execute in the Salt segment. Parkinson still sees risks to 2019 estimates, but views management changes, a likely renegotiation with creditors and the snowfall season as balancing risk/reward.
11/27/18
FBCO
11/27/18
UPGRADE
FBCO
Neutral
Compass Minerals upgraded to Neutral from Underperform at Credit Suisse
CTVA Corteva
$28.30

-0.2 (-0.70%)

08/09/19
RBCM
08/09/19
UPGRADE
Target $38
RBCM
Outperform
Corteva upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital analyst Arun Viswanathan upgraded Corteva to Outperform and raised his price target to $38 from $29 after its Q2 earnings beat. The analyst says that after a year of negative weather in 2019 due to delayed corn and soybean plantings, the impact for ag companies could turn positive in 2020. The analyst also believes that Corteva could generate $2.3B-$2.35B in 2020 EBITDA from deal synergies and "modest" new product growth.
08/09/19
RBCM
08/09/19
UPGRADE
RBCM
Outperform
Corteva upgraded to Outperform from Sector Perform at RBC Capital
08/19/19
SBSH
08/19/19
UPGRADE
SBSH
Buy
Corteva upgraded to Buy from Neutral at Citi
08/19/19
SBSH
08/19/19
UPGRADE
Target $34.5
SBSH
Buy
Citi upgrades Corteva to Buy after tough 2019, says 2020 should be better
As previously reported, Citi analyst P.J. Juvekar upgraded Corteva to Buy from Neutral, stating that he sees a positive path forward going into 2020 after the company "was hit with a confluence of negative factors" in 2019. In the coming year, Corteva has several products in the pipeline, should see strong growth outside the U.S. and can benefit from multiple productivity programs as a new company on top of merger-related synergies, Juvekar tells investors. He edged his price target on Corteva shares up to $34.50 from $34 on higher expected earnings.
ECL Ecolab
$197.09

-2.51 (-1.26%)

08/05/19
BMOC
08/05/19
NO CHANGE
Target $208
BMOC
Market Perform
Ecolab price target raised to $208 from $180 at BMO Capital
BMO Capital analyst John McNulty raised his price target on Ecolab to $208 after its "modest" Q2 earnings beat with a "solid" sales growth in the Industrial segment offsetting the weakness in Energy. The analyst believes that the company's fundamentals should lead to continued double-digit earnings growth in 2019 and 2020 as pricing and "falling raws" offset a challenged macro, but also sees the 20- and 19-times expected 2019 and 2020 EBITDA estimates multiple as "too rich", keeping his Market Perform rating.
07/31/19
FBCO
07/31/19
NO CHANGE
Target $181
FBCO
Neutral
Ecolab price target raised to $181 from $170 at Credit Suisse
Credit Suisse analyst Christopher Parkinson raised his price target for Ecolab to $181 from $170 following quarterly results. The analyst reiterates a Neutral rating on the shares.
05/01/19
ADAM
05/01/19
NO CHANGE
Target $198
ADAM
Buy
Ecolab price target raised to $198 from $186 at Canaccord
Canaccord analyst Chip Moore raised his price target for Ecolab to $198 from $186 following the company's Q1 results, saying he finds Ecolab "very well positioned" to benefit from the convergence of population growth, resource volatility and rapid industrialization across the world. The company's recurring services model drives high visibility, even in a variable macro environment, Moore contends. He maintains a Buy rating.
07/31/19
ADAM
07/31/19
NO CHANGE
Target $222
ADAM
Buy
Ecolab price target raised to $222 from $198 at Canaccord
Canaccord analyst Chip Moore raised his price target on Ecolab to $222 from $198 following Q2 results which indicated strong execution and favorable macro-trends. The analyst said Ecolab is well positioned to benefit from the convergence of population growth, resource volatility, and rapid industrialization across the world. Moore reiterated his Buy rating on Ecolab shares.
WLK Westlake Chemical
$65.34

1.69 (2.66%)

08/16/19
BOFA
08/16/19
DOWNGRADE
BOFA
Underperform
Westlake Chemical downgraded to Underperform from Buy at BofA/Merrill
07/29/19
SBSH
07/29/19
DOWNGRADE
Target $50
SBSH
Neutral
Citi downgrades Dow to Neutral on 'mounting capacity additions'
Citi analyst P.J. Juvekar downgraded Dow Inc. (DOW) to Neutral from Buy and lowered his price target for the shares to $50 from $54. There are "mounting capacity additions" in Dow's three major chains - ethylene, siloxanes, and urethanes, Juvekar tells investors in a research note. As such, the analyst believes fundamental weakness in the company's three major chains is likely to persist. Ethylene stocks have become trading stocks now late in the cycle, says Juvekar. He believes this also has negative implications for LyondellBasell (LYB) and Westlake Chemical (WLK).
08/07/19
NOMU
08/07/19
NO CHANGE
Target $53
NOMU
Reduce
Westlake Chemical price target lowered to $53 from $57 at Nomura Instinet
Nomura Instinet analyst Aleksey Yefremov lowered his price target for Westlake Chemical to $53 from $57 and keeps a Reduce on the shares following the company's Q2 results. The stock's valuation level is "excessive" given the possibility of stalling caustic soda pricing and falling PE prices, Yefremov tells investors in a research note. The analyst remains cautious on caustic soda pricing due to "weak demand globally."
TROX Tronox
$8.93

0.27 (3.12%)

04/11/19
RHCO
04/11/19
NO CHANGE
Target $20
RHCO
Buy
Tronox price target raised to $20 from $17 at SunTrust
SunTrust analyst James Sheehan raised his price target on Tronox to $20 and kept his Buy rating, saying the company's settlement of an antitrust suit involving the proposed Cristal merger is a positive catalyst for the whole titanium dioxide group. The analyst expects Tronox to be the "largest beneficiary" of the settlement and sees the deal closing as imminent. Sheehan adds that the company's expected $700M in proceeds from the sale of its North American TiO2business to INEOS Enterprises should be used for share repurchases.
04/11/19
JPMS
04/11/19
NO CHANGE
Target $17
JPMS
Overweight
Tronox shares 'have room' to rally to $17 near-term, says JPMorgan
Tronox shares, following completion of the Cristal acquisition, "have room" to appreciate shorter-term to reach $17, and the appreciation "will occur in steps," JPMorgan analyst Jeffrey Zekauskas tells investors in a research note. He keeps an Overweight rating on Tronox with a $17 December 2019 price objective. Exxaro owns 28.7M Tronox shares that it intends to monetize and some investors believe these shares have created an "overhang," Zekauskas writes. However, he believes Tronox will repurchase theses shares as well as Exxaro's 26% stake in Tronox's South African joint ventures. The analyst also believes that the major titanium dioxide companies "should begin to experience a healthy demand pattern" in the second half of 2019. Zekauskas expects Tronox to generate $3.00 per share in free cash flow in 2020.
05/06/19
JPMS
05/06/19
DOWNGRADE
Target $34
JPMS
Neutral
JPMorgan downgrades Chemours to Neutral, prefers shares of Tronox
JPMorgan analyst Jeffrey Zekauskas downgraded Chemours (CC) to Neutral from Overweight and lowered his price target for the shares to $34 from $40. The company's Q1 volumes decreased 35% year-over-year, which might be expected in a recession "but it is not any kind of normal result in a growing economy," Zekauskas tells investors in a research note. The analyst decreased his EBITDA expectations, which brought his price target to $34, near the current Chemours share price. He prefers shares of Tronox (TROX) to Chemours.
03/20/19
BMOC
03/20/19
NO CHANGE
Target $19
BMOC
Outperform
Tronox price target raised to $19 from $13 at BMO Capital
BMO Capital analyst John McNulty raised his price target on Tronox to $19 and kept his Outperform rating after the company and regulators moved to put the Cristal transaction for FTC consideration. The analyst states that while the support from the FTC staff does not necessarily guarantee the approval of the Ashtabula sale remedy by the deciding commission, it "dramatically increases the likelihood" of success, and believes that the transaction could close next month. McNulty also sees Tronox as more vertically integrated after the Cristal transaction, forecasting "significant upside" potential for the stock.
STZHF Stelco Holdings
$0.00

(0.00%)

01/14/19
GSCO
01/14/19
DOWNGRADE
GSCO
Neutral
Stelco Holdings downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Matthew Korn downgraded Stelco Holdings to Neutral and lowered his price target for the shares to C$20 from C$27. The company "faces limitations" from easing sheet prices, lingering uncertainty on North America trade policy, and trading liquidity, says the analyst.
SHW Sherwin-Williams
$521.07

6.37 (1.24%)

07/25/19
RBCM
07/25/19
NO CHANGE
Target $550
RBCM
Outperform
Sherwin-Williams price target raised to $550 from $517 at RBC Capital
RBC Capital analyst Arun Viswanathan raised his price target on Sherwin-Williams to $550 and kept his Outperform rating after its Q2 earnings beat, saying the quarter was driven by "strong execution" in its North America retail market and a "favorable" backlog of delayed projects. The analyst notes that the company's comps growth of 4.3% topped his forecast of 3% thanks to the higher sales volume and an increase in selling prices.
07/29/19
BMOC
07/29/19
NO CHANGE
Target $517
BMOC
Market Perform
Sherwin-Williams price target raised to $517 from $473 at BMO Capital
BMO Capital analyst John McNulty raised his price target on Sherwin-Williams to $517 after its Q2 earnings beat, saying the company is generating "solid results" in a difficult market thanks to the pricing power strength and volume growth of its Stores Group. The analyst also keeps his Market Perform rating on the stock given its "lofty valuation".
09/04/19
BMOC
09/04/19
NO CHANGE
Target $550
BMOC
Market Perform
Sherwin-Williams price target raised to $550 from $517 at BMO Capital
BMO Capital analyst John McNulty raised his price target on Sherwin-Williams to $550 after meeting with its CEO, saying the discussions affirmed his view of the stock as a "port in the storm" for investors during challenging macro periods. The analyst also sees the company generating solid long term growth but keeps his Market Perform rating, noting that the stock is already trading at a "lofty" multiple relative to his expected 2019 EBITDA amid continued concerns regarding the U.S. housing market.
09/06/19
JEFF
09/06/19
NO CHANGE
Target $546
JEFF
Hold
Sherwin-Williams price target raised to $546 from $430 at Jefferies
Jefferies analyst Laurence Alexander raised his price target for Sherwin-Williams to $546 from $430 saying the company's forward 12-month returns have a "strong relationship" with mortgage yields, credit spreads and oil prices. There is a "surprising consistency in the way the shares tend to overshoot when the model is bullish," Alexander tells investors in a research note. He believes this framework supports the recent rally in shares of Sherwin-Williams more than he expected. Nonetheless, Alexander keeps a Hold rating on the stock.
POG Patina Oil & Gas
$0.00

(0.00%)

MOS Mosaic
$21.38

1.21 (6.00%)

08/06/19
CIBC
08/06/19
UPGRADE
Target $27
CIBC
Outperformer
Mosaic upgraded to Outperformer from Neutral at CIBC
CIBC analyst Jacob Bout upgraded Mosaic to Outperform but lowered his price target to $27 from $28.
08/07/19
CIBC
08/07/19
UPGRADE
Target $27
CIBC
Outperformer
CIBC upgrades Mosaic after selloff ahead of 'robust' 2020
CIBC analyst Jacob Bout last night upgraded Mosaic to Outperformer from Neutral while lowering his price target for the shares to $27 from $28. The analyst expects a "robust" 2020 for U.S. wholesale fertilizer demand. Further, following the "massive" share selloff post the Q2 results, Mosaic offers a "cost-effective way to gain access to 9+Mt of potash production," Bout tells investors in a research note.
07/31/19
SBSH
07/31/19
UPGRADE
Target $31
SBSH
Buy
Citi gets more positive on Ag ahead of 2020, upgrades Mosaic to Buy
Citi analyst P.J. Juvekar upgraded Mosaic to Buy from Neutral and raised his price target for the shares to $31 from $26. 2020 is shaping up to be a "bumper" year after a "disappointing" 2019 for agriculture due to severe wet weather in the cornbelt, Juvekar tells investors in a research note. The analyst is "getting more positive" on 2020 and "more constructive" on the Ag cycle due to a strong expected season in South America. He thinks the bad news is now priced into Mosaic shares. Juvekar also removed his "Negative Catalyst Watch" on CF Industries (CF) and keeps a Buy rating on the shares with a $48 price target. Nutrien (NTR) remains his top pick and he boosted his price target for the shares to $61 from $56.
07/31/19
SBSH
07/31/19
UPGRADE
SBSH
Buy
Mosaic upgraded to Buy from Neutral at Citi
Citi analyst P.J. Juvekar upgraded Mosaic to Buy from Neutral.
LXU LSB Industries
$5.73

0.485 (9.26%)

LTHM Livent
$6.86

0.1 (1.48%)

05/16/19
ARGS
05/16/19
DOWNGRADE
ARGS
Hold
Livent downgraded to Hold from Buy at Argus
08/12/19
BOFA
08/12/19
DOWNGRADE
Target $7
BOFA
Underperform
Livent downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst Steve Byrne downgraded Livent to Underperform from Neutral and lowered his price target for the shares to $7 from $10. The stock has rallied 34% over the past three trading days despite reporting an inline Q2, Byrne tells investors in a research note. The analyst, however, believes the lithium hydroxide market for electric vehicles may not have enough growth to absorb the new capacity coming over the next 6-12 months. He sees increased risk that Livent's lithium hydroxide production will continue at "challenged economics."
05/22/19
LOOP
05/22/19
NO CHANGE
Target $12
LOOP
Buy
Livent has 'greater value' despite adverse 2019 dynamics, says Loop Capital
Loop Capital analyst Chris Kapsch kept his Buy rating and $12 price target on Livent after meeting with its management this week, saying that while the company's recent "reset" of 2019 EBITDA expectations was "disappointing", he sees the stock remaining supported by the lithium industry's longer-term growth story remaining intact. The analyst expects Livent to become a "more meaningful beneficiary" of the industry's "attractive and sustainable" annualized revenue growth rate of over 20% and, based on the management commentary, believes that an inflection in lithium fundamentals is coming next year.
05/16/19
ARGS
05/16/19
DOWNGRADE
ARGS
Hold
Livent downgraded to Hold from Buy at Argus
Argus analyst Bill Selesky downgraded Livent to Hold after its Q1 earnings last week, saying the management has forecasted weaker demand and pricing for its high-performance lithium hydroxide amid rising uncertainty around electric vehicle subsidies in China. The analyst further cites the company's forecast of no pricing recovery until late 2019 or early 2020 and its guidance cut, also lowering his FY19 EPS view to 61c from $1.09. Selesky maintains his forecast of FY20 EPS at $1.20 given his expectations for a rebound in lithium pricing.
IOSP Innospec
$90.85

1.72 (1.93%)

04/12/19
KEYB
04/12/19
DOWNGRADE
KEYB
Sector Weight
Innospec downgraded to Sector Weight from Overweight at KeyBanc
09/04/19
KING
09/04/19
INITIATION
Target $95
KING
Buy
Innospec initiated with a Buy at CL King
CL King analyst David Silver initiated Innospec with a Buy and $95 price target.
GRA W.R. Grace
$69.78

-0.12 (-0.17%)

04/12/19
KEYB
04/12/19
DOWNGRADE
KEYB
Sector Weight
W.R. Grace downgraded to Sector Weight from Overweight at KeyBanc
07/26/19
BARD
07/26/19
NO CHANGE
Target $81
BARD
Outperform
W.R. Grace weakness a buying opportunity, says Baird
Baird analyst Ben Kallo said he would be an aggressive buyer of W.R. Grace following its selloff after Q2 results. The analyst noted the results beat his estimates but also noted the company reduced its guidance. He said he believes Grace is a high quality name which will be able to effectively navigate near-term challenges. Kallo reiterated his Outperform rating and $81 price target on W.R. Grace shares.
03/21/19
03/21/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Fox Corp. (FOXA) initiated with an Outperform at Credit Suisse. 2. Eagle Materials (EXP) initiated with a Neutral at JPMorgan. 3. The Medicines Co. (MDCO) initiated with a Buy at Roth Capital. 4. PolarityTE (PTE) initiated with an Outperform at Evercore ISI. 5. W.R. Grace (GRA) initiated with a Buy at Berenberg. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/21/19
BREN
03/21/19
INITIATION
Target $95
BREN
Buy
W.R. Grace initiated with a Buy at Berenberg
Berenberg analyst Paretosh Misra initiated W.R. Grace with a Buy and $95 price target.
FMC FMC Corporation
$86.58

-0.46 (-0.53%)

08/09/19
RBCM
08/09/19
UPGRADE
Target $103
RBCM
Outperform
FMC Corporation upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital analyst Arun Viswanathan upgraded FMC Corporation to Outperform and raised his price target to $103 from $87 after its in-line Q2 earnings and raised FY19 guidance. The analyst says his prior view of a patent cliff for the company coming in 2022 was "mistaken", noting that FMC has the "process and formulation patents" protecting Rnaxypyr and Cyazypyr through 2025 and beyond. Viswanathan is also positive on the company's infrastructure and ability to sell AIs to third parties, with his new price target assuming a raised target multiple of 12-times from 11.5-times.
08/02/19
08/02/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. FMC Corporation (FMC) upgraded to Buy from Neutral at Goldman Sachs with analyst Adam Samuelson saying he views FMC as a as "unique crop protection pure-play" with favorable growth prospects related to its diamides business and a "healthy" pipeline of crop protection active ingredients. 2. Pinterest (PINS) upgraded to Buy from Hold at Deutsche Bank with analyst Lloyd Walmsley saying he raised his estimates meaningfully following last night's Q2 results on more confidence that the company can scale its ad business, in the U.S. and internationally, faster than expected. 3. Westpac Banking (WBK) upgraded to Equal Weight from Underweight at Morgan Stanley. 4. Kroger (KR) upgraded to Buy from Hold at Pivotal Research with analyst Ajay Jain saying despite a lack of near-term catalysts, Kroger shares are "simply mispriced at this time." 5. SurveyMonkey (SVMK) upgraded to Buy from Neutral at UBS with analyst Eric Sheridan saying the company's execution points towards "strong" compounding growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/02/19
GSCO
08/02/19
UPGRADE
Target $100
GSCO
Buy
FMC Corporation assumed with a Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Adam Samuelson upgraded FMC Corporation to Buy from Neutral after assuming coverage of the name and raised his price target for the shares to $100 from $88. The analyst views FMC as a as "unique crop protection pure-play" with favorable growth prospects related to its diamides business and a "healthy" pipeline of crop protection active ingredients. The company should hit its target of 5%-7% annual revenue growth through 2023, more than twice the growth expected from the crop chemical market, Samuelson tells investors in a research note. He sees FMC's growth coming from new products, formulations, and market penetration of diamides.
08/09/19
RBCM
08/09/19
UPGRADE
RBCM
Outperform
FMC Corporation upgraded to Outperform from Sector Perform at RBC Capital

TODAY'S FREE FLY STORIES

PG

Procter & Gamble

$122.22

0.37 (0.30%)

, KO

Coca-Cola

$53.90

-0.62 (-1.14%)

08:17
09/21/19
09/21
08:17
09/21/19
08:17
Periodicals
Kellogg, Coca-Cola among staples stocks for dividends, Barron's says »

Consumer-staples stocks…

PG

Procter & Gamble

$122.22

0.37 (0.30%)

KO

Coca-Cola

$53.90

-0.62 (-1.14%)

PEP

PepsiCo

$134.49

-0.98 (-0.72%)

CL

Colgate-Palmolive

$70.97

0.01 (0.01%)

KMB

Kimberly-Clark

$135.13

0.9 (0.67%)

K

Kellogg

$63.79

0.07 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 01

    Oct

  • 03

    Oct

  • 08

    Oct

  • 18

    Oct

  • 22

    Oct

  • 29

    Oct

  • 01

    Nov

CMCSA

Comcast

$46.36

-0.32 (-0.69%)

, CMCSK

Comcast

$0.00

(0.00%)

08:09
09/21/19
09/21
08:09
09/21/19
08:09
Periodicals
Facebook, Microsoft among growth stocks for risky times, Barron's says »

Comcast (CMCSA), Delta…

CMCSA

Comcast

$46.36

-0.32 (-0.69%)

CMCSK

Comcast

$0.00

(0.00%)

DAL

Delta Air Lines

$58.63

-0.05 (-0.09%)

FANG

Diamondback Energy

$96.90

-0.45 (-0.46%)

EHC

Encompass Health

$64.41

-0.01 (-0.02%)

FB

Facebook

$189.88

-0.27 (-0.14%)

JNJ

Johnson & Johnson

$131.73

1.75 (1.35%)

MSFT

Microsoft

$139.34

-1.74 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 01

    Oct

  • 02

    Oct

  • 15

    Oct

  • 24

    Oct

  • 27

    Oct

YUM

Yum! Brands

$112.31

-1.83 (-1.60%)

, MCD

McDonald's

$209.44

-1.12 (-0.53%)

08:05
09/21/19
09/21
08:05
09/21/19
08:05
Periodicals
Fast food stock could gain if consumer spending slows, Barron's says »

Despite a surge in second…

YUM

Yum! Brands

$112.31

-1.83 (-1.60%)

MCD

McDonald's

$209.44

-1.12 (-0.53%)

CMG

Chipotle

$835.17

3.67 (0.44%)

CBRL

Cracker Barrel

$166.12

-0.23 (-0.14%)

WEN

Wendy's

$20.77

0.22 (1.07%)

QSR

Restaurant Brands

$72.64

-1.24 (-1.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 01

    Oct

  • 10

    Oct

  • 22

    Oct

  • 12

    Nov

  • 13

    Nov

SFTBF

SoftBank

$0.00

(0.00%)

, SFTBY

SoftBank

$0.00

(0.00%)

08:00
09/21/19
09/21
08:00
09/21/19
08:00
Periodicals
Softbank stock still attractive, Barron's says »

Investors seem convinced…

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REAL

RealReal

$17.00

0.21 (1.25%)

07:57
09/21/19
09/21
07:57
09/21/19
07:57
Periodicals
RealReal among year's more under-the-radar IPOs, Barron's says »

The RealReal is one of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVS

CVS Health

$64.28

0.65 (1.02%)

, WAB

Wabtec

$74.01

0.26 (0.35%)

07:48
09/21/19
09/21
07:48
09/21/19
07:48
Periodicals
Opioid crisis could hurt investors, Barron's says »

Opioid lawsuits have…

CVS

CVS Health

$64.28

0.65 (1.02%)

WAB

Wabtec

$74.01

0.26 (0.35%)

ABC

AmerisourceBergen

$85.13

0.475 (0.56%)

CAH

Cardinal Health

$47.89

-0.14 (-0.29%)

MCK

McKesson

$146.83

1.06 (0.73%)

MYL

Mylan

$21.01

0.03 (0.14%)

AMRX

Amneal Pharmaceuticals

$3.34

0.21 (6.71%)

ABT

Abbott

$83.56

0.35 (0.42%)

MNK

Mallinckrodt

$2.46

0.01 (0.41%)

ENDP

Endo

$3.48

0.115 (3.42%)

TEVA

Teva

$7.44

-0.08 (-1.06%)

JNJ

Johnson & Johnson

$131.73

1.75 (1.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 01

    Oct

  • 02

    Oct

  • 15

    Oct

  • 16

    Oct

  • 23

    Oct

  • 06

    Nov

  • 13

    Nov

DDAIF

Daimler AG

$0.00

(0.00%)

, FCAU

Fiat Chrysler

$13.52

-0.11 (-0.81%)

07:13
09/21/19
09/21
07:13
09/21/19
07:13
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$13.52

-0.11 (-0.81%)

F

Ford

$9.16

0.06 (0.66%)

GM

General Motors

$37.37

-0.41 (-1.09%)

HMC

Honda

$26.68

0.03 (0.11%)

NSANY

Nissan

$0.00

(0.00%)

TSLA

Tesla

$240.62

-5.89 (-2.39%)

TM

Toyota

$136.72

0.12 (0.09%)

VWAGY

Volkswagen

$0.00

(0.00%)

FB

Facebook

$189.88

-0.27 (-0.14%)

AGU

Agrium

$0.00

(0.00%)

ANDE

Andersons

$26.28

-0.56 (-2.09%)

ADM

Archer Daniels

$40.94

0.05 (0.12%)

BG

Bunge

$55.91

-0.26 (-0.46%)

CF

CF Industries

$49.28

-0.76 (-1.52%)

CMP

Compass Minerals

$56.29

-1.765 (-3.04%)

IPI

Intrepid Potash

$3.43

0.01 (0.29%)

POT

Potash

$0.00

(0.00%)

SYT

Syngenta

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

  • 02

    Oct

  • 23

    Oct

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

  • 13

    Nov

UPS

UPS

$120.71

1.61 (1.35%)

21:22
09/20/19
09/20
21:22
09/20/19
21:22
Conference/Events
UPS management to meet with UBS »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

DIS

Disney

$132.18

-1.14 (-0.86%)

, T

AT&T

$37.92

0.78 (2.10%)

18:17
09/20/19
09/20
18:17
09/20/19
18:17
Periodicals
Disney reaches TV carriage agreement with AT&T, Bloomberg says »

The deal includes ESPN on…

DIS

Disney

$132.18

-1.14 (-0.86%)

T

AT&T

$37.92

0.78 (2.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

BA

Boeing

$379.33

-5.28 (-1.37%)

18:15
09/20/19
09/20
18:15
09/20/19
18:15
Periodicals
Icelandair reaches deal for Boeing to cover costs associated with 737, WSJ says »

Icelandair Group said it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

MCF

Contango Oil & Gas

$1.71

-0.07 (-3.93%)

17:58
09/20/19
09/20
17:58
09/20/19
17:58
Hot Stocks
Karlin Asset Management reports 11.4% passive stake in Contango Oil & Gas »

Karlin Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Shares

$142.97

1.68 (1.19%)

17:41
09/20/19
09/20
17:41
09/20/19
17:41
Hot Stocks
SPDR Gold Shares holdings rise to 894.15MT from 883.60MT »

This is the highest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VXRT

Vaxart

$0.58

-0.0307 (-5.03%)

17:37
09/20/19
09/20
17:37
09/20/19
17:37
Syndicate
Vaxart files to sell 15.6M shares of common stock »

H.C. Wainwright acted as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$217.69

-3.22 (-1.46%)

17:34
09/20/19
09/20
17:34
09/20/19
17:34
Periodicals
Apple given tariff exclusion on certain Mac Pro parts, Bloomberg says »

Apple has received U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IIVI

II-VI

$39.05

-0.5 (-1.26%)

, CPE

Callon Petroleum

$4.53

-0.015 (-0.33%)

17:31
09/20/19
09/20
17:31
09/20/19
17:31
Hot Stocks
II-VI to enter S&P 400; Callon Petroleum, PriceSmart to enter S&P SmallCap600 »

S&P SmallCap 600…

IIVI

II-VI

$39.05

-0.5 (-1.26%)

CPE

Callon Petroleum

$4.53

-0.015 (-0.33%)

PSMT

PriceSmart

$60.29

-0.39 (-0.64%)

FNSR

Finisar

$24.31

1.25 (5.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 02

    Oct

  • 30

    Oct

NVR

NVR

$3,632.55

-30.45 (-0.83%)

, JEF

Jefferies Financial Group

$19.47

-0.19 (-0.97%)

17:26
09/20/19
09/20
17:26
09/20/19
17:26
Hot Stocks
NVR to replace Jefferies Financial Group in the S&P 500 at open on September 26 »

NVR (NVR) will replace…

NVR

NVR

$3,632.55

-30.45 (-0.83%)

JEF

Jefferies Financial Group

$19.47

-0.19 (-0.97%)

SPB

Spectrum Brands

$49.66

-1.395 (-2.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

NOC

Northrop Grumman

$368.25

-7.45 (-1.98%)

17:24
09/20/19
09/20
17:24
09/20/19
17:24
Hot Stocks
Northrop Grumman subsidiary awarded $1.12B Missile Defense Agency contract »

Orbital Sciences, or OSC,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSMT

PriceSmart

$60.29

-0.39 (-0.64%)

, FNSR

Finisar

$24.31

1.25 (5.42%)

17:23
09/20/19
09/20
17:23
09/20/19
17:23
Hot Stocks
Breaking Hot Stocks news story on PriceSmart, Finisar »

PriceSmart to replace…

PSMT

PriceSmart

$60.29

-0.39 (-0.64%)

FNSR

Finisar

$24.31

1.25 (5.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

IIVI

II-VI

$39.05

-0.5 (-1.26%)

, CPE

Callon Petroleum

$4.53

-0.015 (-0.33%)

17:22
09/20/19
09/20
17:22
09/20/19
17:22
Hot Stocks
Breaking Hot Stocks news story on II-VI, Callon Petroleum »

II-VI to replace Callon…

IIVI

II-VI

$39.05

-0.5 (-1.26%)

CPE

Callon Petroleum

$4.53

-0.015 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 02

    Oct

NVR

NVR

$3,632.55

-30.45 (-0.83%)

17:20
09/20/19
09/20
17:20
09/20/19
17:20
Hot Stocks
Breaking Hot Stocks news story on NVR »

NVR to replace Jefferies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NHYDY

Norsk Hydro

$0.00

(0.00%)

17:12
09/20/19
09/20
17:12
09/20/19
17:12
Hot Stocks
Norsk Hydro discloses federal court in Brazil lifts embargo on Alunortes »

The Federal Court in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RESN

Resonant

$3.05

0.02 (0.66%)

17:03
09/20/19
09/20
17:03
09/20/19
17:03
Conference/Events
Resonant participates in a conference call with Loop Capital »

Semiconductor Analysts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 12

    Nov

NINE

Nine Energy Services

$6.73

-0.33 (-4.67%)

17:02
09/20/19
09/20
17:02
09/20/19
17:02
Syndicate
Breaking Syndicate news story on Nine Energy Services »

Nine Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATOM

Atomera

$3.70

0.17 (4.82%)

17:00
09/20/19
09/20
17:00
09/20/19
17:00
Conference/Events
Atomera participates in a conference call with Loop Capital »

Semiconductor Analysts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPWR

Monolithic Power

$154.21

-2 (-1.28%)

16:50
09/20/19
09/20
16:50
09/20/19
16:50
Conference/Events
Monolithic Power participates in a conference call with Loop Capital »

Semiconductor Analysts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.